Experienced physician-scientist and life science executive, Dr. Redig will steer InduPro’s development strategy as the Company advances its lead program toward Phase 1 Studies SEATTLE, WA and CAMBRIDGE, MA— May 27, 2025 — InduPro, Inc., a biotechnology company defining membrane protein spatial relationships to create novel therapeutics for the treatment of cancer and autoimmune diseases, […]

Just a month af­ter strik­ing a part­ner­ship with Sanofi on an au­toim­mune dis­ease pro­gram, InduPro Ther­a­peu­tics has land­ed a sec­ond phar­ma part­ner­ship fo­cused on de­vel­op­ing… More

InduPro will leverage its proprietary platform to develop bi- and trispecific therapeutics that discover rationally selected Tumor Associated Proximity Antigens (TAPAs) to pair as co-targets with Tumor Associated Antigens, in collaboration with Lilly.

SEATTLE, WA and CAMBRIDGE, MA— December 10, 2025 — InduPro, Inc., today announced a strategic equity investment and research collaboration with Sanofi. The agreement with Sanofi includes the right of first negotiation for InduPro’s bispecific PD-1 agonist program, which is currently in preclinical development for the treatment of autoimmune and inflammatory disorders.